Ask AI
Managing AEs in Relapsed ES-SCLC

CE / CME

Mitigating and Managing AEs Associated With Newer Agents for Relapsed ES-SCLC

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Released: December 02, 2025

Expiration: June 01, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 62-year-old woman with relapsed extensive-stage (ES) small-cell lung cancer (SCLC) and Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 is receiving cycle 1 Day 1 of tarlatamab (1 mg IV) in the outpatient setting and 8 hours post infusion, she develops a temperature of 38.7°C with mild tachycardia (heart rate 104 beats/min). In addition to ruling out infection, what is the most appropriate next step in her management?

2.

A 63-year-old patient with relapsed ES-SCLC is starting treatment with single-agent lurbinectedin. What would you tell him about expected adverse events (AEs)?